Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Peer Review reports

Original Submission
10 Sep 2020	Submitted	Original manuscript
15 Oct 2020	Reviewed	Reviewer Report - Heike Niessner
19 Nov 2020	Reviewed	Reviewer Report
3 Dec 2020	Author responded	Author comments - Khanh B Tran
Resubmission - Version 2
3 Dec 2020	Submitted	Manuscript version 2
4 Dec 2020	Reviewed	Reviewer Report - Heike Niessner
4 Jan 2021	Reviewed	Reviewer Report
18 Jan 2021	Author responded	Author comments - Khanh B Tran
Resubmission - Version 3
18 Jan 2021	Submitted	Manuscript version 3
Publishing
20 Jan 2021	Editorially accepted
6 Feb 2021	Article published	10.1186/s12885-021-07826-4

Back to article page